SecBot SecBot
8-K ·Filed Jul 29, 2026

IONS

IONIS PHARMACEUTICALS INC
NEUTRAL
Impact 5/10
Horizonweeks Processed3mo ago SEC0001140361-26-029960
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Revenue beat consensus by 41% but the beat is largely from non-recurring R&D milestone payments; watch for the zilganersen PDUFA on Sep 22, 2026 and the pelacarsen Lp(a) HORIZON data later this year as the next major catalysts. The CARDIO-TTRansform miss removes a potential upside driver for eplontersen royalties.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

IONS drug pipeline →

diranersen

● Neutral Named in this 8-K
Impact
Phase
Phase 2 (topline readout complete; confirmatory Phase 3 announced but not yet started)
Time to market
Unknown and several years away — a confirmatory Phase 3 program has not even started; the completed Phase 2 CELIA trial's estimated overall completion is January 2029, so a registration and launch would come later than that if Phase 3 succeeds.
Next catalyst
None dated

What to watchWatch for Biogen's announcement of the Phase 3 program design, start date, and endpoints, that will be the next share-moving event, but it is likely months away and not a binary. Near-term BIIB stock moves are driven mostly by the commercial franchises (LEQEMBI, SPINRAZA) and other pipeline news, not diranersen, so treat this as years-out call-option value rather than a trade catalyst.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$54.04
T+0 close · Jul 29, 2026 · via day close
Latest settled
−18.75%
T+60 · $43.91
Vs SPY
−23.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 29 $54.04entry
  2. T+1 · 4mo ago −1.41%α −3.08% · $53.28
  3. T+5 · 3mo ago +0.28%α −5.25% · $54.19
  4. T+20 · 3mo ago +17.25%α +12.23% · $63.36
  5. T+60 · 26d ago −18.75%α −23.47% · $43.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ionis reported Q2 2026 total revenue of $268M, up 56% YoY excluding a one-time 2025 sapablursen payment, but GAAP net loss widened to $115M from a $124M profit in Q2 2025 which included a $280M upfront. Commercial revenue grew 15% YoY driven by DAWNZERA ($26M, +63% QoQ) and early TRYNGOLZA sHTG launch momentum. The company maintained full-year 2026 guidance and reiterated its 2028 cash-flow breakeven target.

Key Financial Metrics

Revenue
$268.0M
est $190.1M · +41.0%
Guidance
$875M-$900M
maintained

Key Facts

  • Q2 2026 total revenue $268M vs $452M in Q2 2025 (Q2 2025 included $280M sapablursen upfront); ex that item, revenue +56% YoY
  • Non-GAAP net loss $70M vs non-GAAP net income $154M in Q2 2025
  • TRYNGOLZA net product sales $5M in Q2, $32M H1; on track for full-year $100-110M guidance
  • DAWNZERA net product sales $26M in Q2, +63% QoQ; on track for full-year $110-120M guidance
  • Cash and short-term investments $2.1B at June 30, 2026, down from $2.7B at Dec 31, 2025 due to convertible note repayment
  • Phase 3 CARDIO-TTRansform study of eplontersen in ATTR-CM missed primary composite endpoint
  • Full-year 2026 guidance maintained: total revenue $875-900M, non-GAAP operating loss $425-475M

Financial Impact

Q2 revenue $268M (consensus $190.1M); GAAP EPS -$0.69 (consensus -$0.88); beat on both lines

revenueepscash

Segment Breakdown

SegmentRevenueGrowth
Commercial revenue$119.0M+15.5%
R&D revenue$149.0MNot reported

Risk Factors

  • CARDIO-TTRansform miss reduces WAINUA ATTR-CM opportunity
  • TRYNGOLZA sHTG launch still early; full-year guidance implies significant H2 ramp
  • Operating cash burn continues; $2.1B cash runway supports operations but convertible debt maturities remain

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-029960
Document: ef20078953_8k.htm0001140361-26-029960
Document: 0001140361-26-029960-index-headers.html0001140361-26-029960
Document: 0001140361-26-029960-index.html0001140361-26-029960
Document: 0001140361-26-029960.txt0001140361-26-029960
8-K Data (Synthetic)0001140361-26-029960

Track record

26 reports on IONS

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +32.25% at T+60 after the Jul 9, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $31.00 to $28.01 Now $28.01 +9.65% ▲ +9.65% +7.95% vs SPY
  2. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $44.90 to $40.15 Now $28.01 −37.62% ▼ −10.58% −9.87% vs SPY
  3. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $42.93 to $43.52 Now $28.01 −34.75% ▲ +1.37% +1.93% vs SPY
  4. Oct 21, 202626d ago 8-K Bullish 7/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
  5. Oct 21, 202626d ago Institutional Cluster Mixed 3/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
  6. Sep 23, 20267w ago 8-K Bullish 7/10 Entry $43.93 to $44.65 Now $28.01 −36.24% ▲ +1.64% +2.31% vs SPY
  7. Sep 4, 202610w ago 8-K Bearish 7/10 Entry $56.71 to $47.25 Now $28.01 +50.61% ▲ +16.68% +15.56% vs SPY
  8. Sep 4, 202610w ago 8-K Bullish 7/10 Entry $58.09 to $51.44 Now $28.01 −51.78% ▼ −11.45% −10.24% vs SPY
  9. Jul 31, 202615w ago Insider Buy Neutral 4/10 Entry $54.49 to $56.94 Now $28.01 −48.60% ▲ +4.50% +2.47% vs SPY
  10. Jul 29, 202615w ago 8-K Neutral 5/10 Viewing Entry $54.04 to $54.19 Now $28.01 −48.17% ▲ +0.28% −5.25% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 29, 2026